CN107744591A - 一种抗癌、治癌的纯食品制剂 - Google Patents
一种抗癌、治癌的纯食品制剂 Download PDFInfo
- Publication number
- CN107744591A CN107744591A CN201710662824.9A CN201710662824A CN107744591A CN 107744591 A CN107744591 A CN 107744591A CN 201710662824 A CN201710662824 A CN 201710662824A CN 107744591 A CN107744591 A CN 107744591A
- Authority
- CN
- China
- Prior art keywords
- parts
- cancer
- food formulation
- pure food
- anticancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 60
- 201000011510 cancer Diseases 0.000 title claims abstract description 54
- 235000013305 food Nutrition 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 238000009472 formulation Methods 0.000 title claims abstract description 34
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 18
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 23
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 23
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 18
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 17
- 240000005319 Sedum acre Species 0.000 claims abstract description 16
- 235000014327 Sedum acre Nutrition 0.000 claims abstract description 16
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 7
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 244000000231 Sesamum indicum Species 0.000 claims 1
- 235000003434 Sesamum indicum Nutrition 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229930003944 flavone Natural products 0.000 description 6
- 235000011949 flavones Nutrition 0.000 description 6
- 244000025254 Cannabis sativa Species 0.000 description 4
- 244000292693 Poa annua Species 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 235000015468 Lycium chinense Nutrition 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XXLFLUJXWKXUGS-UHFFFAOYSA-N 6-methoxyquinoline-4-carboxylic acid Chemical compound N1=CC=C(C(O)=O)C2=CC(OC)=CC=C21 XXLFLUJXWKXUGS-UHFFFAOYSA-N 0.000 description 2
- 241000544270 Angelica acutiloba Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 240000007171 Imperata cylindrica Species 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 244000283482 Alloteropsis cimicina Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 235000017898 Digitaria ciliaris Nutrition 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- -1 flavones Flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种抗癌、治癌的纯食品制剂，该纯食品制剂包括绿景天、核肽生物酸、冬虫夏草、枸杞、灵芝、当归。以质量份计，该纯食品制剂包括以下组份：绿景天10‑30份、核肽生物酸3‑5份、冬虫夏草1‑3份、枸杞2‑4份、灵芝1‑3份、当归3‑5份。本发明一种抗癌、治癌的纯食品制剂不但能够抵抗癌症，还可以有效的控制癌症。
Description
技术领域
本发明涉及一种用于能够治疗癌症的药物，尤其是一种抗癌、治癌的纯 食品制剂。
背景技术
癌症(cancer)也称恶性肿瘤，和它相对的是良性肿瘤。癌症是由于机 体细胞失去正常调控，过度增殖而引起的疾病。过度增殖的细胞称癌细胞， 癌细胞常可侵犯周围组织(浸润，invasion)，甚至可经体内循环系统和/或淋 巴系统转移到身体其他部分(癌症转移)。癌症有许多类型，而病症的严重程 度取决于癌细胞所在部位、恶性程度及是否发生转移。一旦确诊，常以结合 手术、化疗和放疗的方式进行治疗。如果癌症未经治疗，通常最终结果将导 致死亡。直到发现癌症是由异常细胞所引起的疾病之前，根据体液理论的治 疗方式仍旧普遍使用来治疗癌症。即使治疗方法并未改变，在16世纪与17 世纪时，经医生解剖尸体寻找病因变得较可为大众接受。德国教授威赫姆· 法布里认为乳癌是由乳汁在输乳管中造成的凝块引起。荷兰教授法兰柯斯· 狄·拉·波·希维斯，相信所有疾病都是化学反应的结果，而酸性淋巴液则是癌 症的起因。他的同侪尼可雷斯·托普则认为癌症是一种慢慢地散播且具传染性 的毒物。到了18世纪，由于显微镜的普遍使用，科学家发现了“癌毒”会从 原本肿瘤生长处透过淋巴结转移到身体其他部位(远端转移)。但是由于卫生 的问题，以手术治疗癌症并无法有很好的结果。有名的苏格兰外科医生亚历 山德·蒙罗在60名手术成功的病例中，仅2名乳癌患者存活二年以上。进入19世纪后，无菌法的使用改善了外科手术的卫生情形，并且也让术后存活率 上升。使得外科手术切除肿瘤成为癌症主要治疗方式。19世纪末期时的威廉 ·科莱(英语：William Coley)则认为治疗的成功率在无菌手术施行之前反而 更高(威廉·科莱曾以注射细菌进入肿瘤的方法想要治疗癌症，但结果并不明 显)，癌症治疗变成根据各个外科医生在去除肿瘤上的不同想法来施行。同一 时期，人的身体为不同的组织构成，组织则由细胞组成的观念兴起，体液理 论有关体内化学不平衡的说法都被放置一旁。细胞病理学的时代正式来临。 2015年10月16日，首都国际癌症论坛召开，中国抗癌协会秘书长王瑛说， 据2012年癌症有关报告显示，中国每年新发癌症病例约337万，死亡约211 万。“癌症已成为我国死亡第一大原因，死亡人数占全球癌症死亡人数四分之 一。”2012年世界癌症报告显示，每年癌症新发病例约1400万，死亡约800万，我国新发病例占全球新发病例22％，死亡人数占26％，超过全球癌症死 亡人数的四分之一。男性当中肺癌发病率最高，女性是乳腺癌。人们对癌症 的恐惧心理以及癌痛给患者带来的极大痛苦，肉体的巨大疼痛伴随着焦虑、 烦躁、抑郁、绝望等不良情绪，加上传统放化疗手段对患者正常细胞误伤带 来的疼痛感，往往超出了他们的承受符合。所以，在癌症的治疗过程中，对 癌痛的抑制和缓解尤为关键，因此，需要设计一种能够抗癌、治癌的新型药 物。
发明内容
针对现有的技术中的缺陷，提供一种抗癌、治癌的纯食品制剂。
本发明通过下述方案实现：
一种抗癌、治癌的纯食品制剂，该纯食品制剂包括绿景天、核肽生物酸、 冬虫夏草、枸杞、灵芝、当归。
以质量份计，该纯食品制剂包括以下组份：绿景天10-30份、核肽生物 酸3-5份、冬虫夏草1-3份、枸杞2-4份、灵芝1-3份、当归3-5份。
以质量份计，该纯食品制剂包括以下组份：绿景天20份、核肽生物酸4 份、冬虫夏草2份、枸杞3份、灵芝2份、当归4份。
该纯食品制剂为颗粒剂、水溶剂、胶囊或者丸剂。
本发明的有益效果为：
本发明一种抗癌、治癌的纯食品制剂不但能够抵抗癌症，还可以有效的 控制癌症。
具体实施方式
下面对本发明优选的实施例进一步说明：
实施例1
一种抗癌、治癌的纯食品制剂，该纯食品制剂包括绿景天、核肽生物酸、 冬虫夏草、枸杞、灵芝、当归。
以质量份计，该纯食品制剂包括以下组份：绿景天20份、核肽生物酸4 份、冬虫夏草2份、枸杞3份、灵芝2份、当归4份。
该纯食品制剂为颗粒剂。
实施例2
一种抗癌、治癌的纯食品制剂，该纯食品制剂包括绿景天、核肽生物酸、 冬虫夏草、枸杞、灵芝、当归。
以质量份计，该纯食品制剂包括以下组份：绿景天30份、核肽生物酸3 份、冬虫夏草3份、枸杞2份、灵芝3份、当归3份。
该纯食品制剂为水溶剂。
实施例3
一种抗癌、治癌的纯食品制剂，该纯食品制剂包括绿景天、核肽生物酸、 冬虫夏草、枸杞、灵芝、当归。
以质量分计，该纯食品制剂包括以下组份：绿景天10份、核肽生物酸5 份、冬虫夏草1份、枸杞4份、灵芝1份、当归5份。
该纯食品制剂为胶囊或者丸剂。可以根据需要制作成不同的制剂。在实 际使用中，本发明的各个食材价格低廉，可以长期使用。
绿景天的黄酮含量特别高，钙含量是牛奶的两倍，且比牛奶易吸收，绿 景天主要成分生物碱、齐墩果酸、果腊、黄酮类、多种维生素和有机酸等， 药理作用宁心、平肝、清热、活血，排毒经常食用能有效治疗高血压和心脏 病，并能保护肝脏。黄酮的神奇功效作用(1)黄酮能杀灭细菌。普通茶隔夜 不能喝，易变馊，而含黄酮的茶如茅岩莓能杀灭细菌，沏泡一星期仍可饮用； 喝中西药不能用普通茶送服，茶叶解药性，用茅岩莓茶送服不但不解药性，而且可辅助中、西药发挥更好的效果。(2)茅岩莓的活性黄酮能杀菌抗炎、 清热解毒、镇痛消肿。可以增进伤口愈合和止痛，栎素由于具有强抗组织胺 性，可以用于各类敏感症。(3)降血压，降血脂，降血糖，降低胆固醇；(4) 能排出人体的有害酸酞和酮体，消除血液里的血垢，调节血脂、血压、软化 血管，抑制血小板聚集，抗血栓。大大降低了心脑血管疾病的发病率，也可 改善心脑血管疾病的症状。(5)调节肾功能，加强肾小管的重吸收，防治尿 频尿急；(6)抗肿瘤，防癌抗癌；(7)调节肠胃，增强脾胃功能；(8)改善 睡眠，防治失眠；(9)黄酮是一种很强的抗氧剂，可有效清除体内的氧自由 基，如花青素可以抑制油脂性过氧化物的全阶段溢出，这种阻止氧化的能力 是维生素E的十倍以上，这种抗氧化作用可以阻止细胞的退化、衰老，提高 人体免疫力，祛病强身，延年益寿；(10)特别能润喉止咳，对金黄葡萄球菌、 甲、乙型链球菌、肺炎双球菌、流感杆菌等有很强的杀灭能力。能治疗感冒、 上呼吸道感染、急慢性咽炎、支气管炎、肺炎；(11)尤其对神经系统疾病效 果明显。
现代药理学研究结果证实，冬虫草含有虫草多糖，虫草酸约7％，碳水 化合物约28.9％，脂肪约8.4％，蛋白质约25％，脂肪中80％以上为不饱和脂 肪酸，蛋白质中包含18种氨基酸，此外，尚含有多种维生素与矿物质、抗菌 活性物质、生物碱、新型免疫抑制剂、超氧化物歧化酶、麦角脂醇、六碳糖 醇等。冬虫夏草中含水分10.85％，脂肪8.50％，粗蛋白25.3％，粗纤维18.55％， 碳水化物28.90％，灰分4.80％。脂肪含饱和脂肪酸13.00％，不饱和脂肪酸 82.2％。此外，还含虫草酸约7％，是奎宁酸的异构物。又含冬虫夏草素，是 一种淡黄色结晶粉末，在试管内能抑制链球菌、鼻疽杆菌、炭疽杆菌、猪出 血性败血症杆菌及葡萄状球菌的生长。另含维生素B120.29μg/100g。
枸杞出自《名医别录》：枸杞，生常山平泽及诸丘陵阪岸。《梦溪笔谈》： 枸杞，陕西极边生者，高丈余，大可柱，叶长数寸，无刺，根皮如厚朴，甘 美异于他处者。《千金翼》云，甘州者为真，叶厚大者是。大体出河西诸郡， 其次江池间圩埂上者。实圆如樱桃。全少核，暴干如饼，极膏润有味。《本草 本草衍义》：枸杞当用梗皮，地骨当用根皮，枸杞子当用其红实，是一物有三 用。其皮寒，根大寒，子微寒，亦三等，今人多用其子，直为补肾药，是曾 未考究《经》意，当更量其虚实、冷热用之。《纲目》：古者枸杞、地骨皮取 常山者为上，其它丘陵阪岸者可用，后世惟取陕西者良，而又以甘州者为绝 品，今陕西之兰州、灵州、九原以西，枸杞并是大树，其叶厚、根粗；河西 及甘州者，其子圆如樱桃，暴干紧小，少核，干亦红润甘美，味如葡萄，可 作果食，异于他处者。大抵以河西者为上也。枸杞(Barbary Wolfberry Fruit) 是名贵的药材和滋补品，中医很早就有“枸杞养生”的说法。《本草纲目》记 载：“枸杞，补肾生精，养肝……明目安神，令人长寿。
灵芝：治愈万症，其功能应验，灵通神效，故名灵芝，又名“不死药” 俗称“灵芝草灵芝孢子褐色，卵形，一端平截，(8.5～ll.2)um×(5.2-6.9)um， 具双层壁。在每个孢子的褐色内层产生许多针状小突起，深深地伸入孢子壁 的透明外层，外层孢壁光滑。灵芝孢子包裹的两层壁十分坚韧，一般的化学， 物理方法很难将其打破，故限制了对其化学成分、生物活性成分的研究。建 立有效的破壁方法，可以促进对其生物活性成分的提取及药用价值的研究。 相当具有营养价值
当归全归长略呈圆柱形，下部有支根3～5条或更多，长15～25cm。外 皮细密，表面黄棕色至棕褐色，具纵皱纹及横长皮孔。根头(归头)直径1.5～ 4cm，具环纹，上端圆钝，有紫色或黄绿色的茎及叶鞘的残基；主根(归身)表 面凹凸不平；支根(归尾)直径0.3～1cm,上粗下细，多扭，有少数须根痕。质柔 韧，断面黄白色或淡黄棕色，皮部厚，有裂隙及多数棕色点状分泌腔，木部 色较淡，形成层环黄棕色。木质部色较淡；根茎部分断面中心通常有髓和空腔。 甘、辛，温。归肝、心、脾经。柴性大、干枯无油或断面呈绿褐色者不可供 药用。稆国权等于1986年对甘肃岷县当归的五种多糖样品进行小鼠体内抗肿 瘤药物筛选，结果，各多糖样品对大鼠移植性肿瘤EC、Hep、S180、Lewis、 B16等瘤株具有一定程度的抑制作用，其肿瘤生长抑制率可达39％，副作用 较少，且可长期用药。如将当归多糖与某些化学药联合应用，可望在治疗上 起到协同作用，并能减轻化疗药物的副作用。KumazawaY.等报道，给接种EC的小鼠sc东当归多糖可明显延长动物生存期。若东当归多糖与巨噬细胞 激活因子同时存在时，激活的巨噬细胞可表现对EL-4白血病细胞的溶细胞 作用。但目前还不清楚当归多糖的抗肿瘤活性是否与体内介导干扰素的产生、 激活巨噬细胞和(或)自然杀伤细胞有关。顾远锡等观察到当归多糖对正常 小鼠、肿瘤小鼠和X线照射的肿瘤小鼠的外周血T和B淋巴细胞数量有明显 影响。故有人推测当归多糖的抗肿瘤作用可能同增加机体免疫功能有密切关 系。
本发明一种抗癌、治癌的纯食品制剂不但能够抵抗癌症，还可以有效的 控制癌症。
尽管已经对本发明的技术方案做了较为详细的阐述和列举，应当理解， 对于本领域技术人员来说，对上述实施例做出修改或者采用等同的替代方案， 这对本领域的技术人员而言是显而易见，在不偏离本发明精神的基础上所做 的这些修改或改进，均属于本发明要求保护的范围。
Claims (4)
1.一种抗癌、治癌的纯食品制剂，其特征在于：该纯食品制剂包括绿景天、核肽生物酸、冬虫夏草、枸杞、灵芝、当归。
2.根据权利要求1所述的一种抗癌、治癌的纯食品制剂，其特征在于，以质量份计，该纯食品制剂包括以下组份：绿景天10-30份、核肽生物酸3-5份、冬虫夏草1-3份、枸杞2-4份、灵芝1-3份、当归3-5份。
3.根据权利要求1所述的一种抗癌、治癌的纯食品制剂，其特征在于，以质量份计，该纯食品制剂包括以下组份：绿景天20份、核肽生物酸4份、冬虫夏草2份、枸杞3份、灵芝2份、当归4份。
4.根据权利要求1所述的一种抗癌、治癌的纯食品制剂，其特征在于，该纯食品制剂为颗粒剂、水溶剂、胶囊或者丸剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710662824.9A CN107744591A (zh) | 2017-08-04 | 2017-08-04 | 一种抗癌、治癌的纯食品制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710662824.9A CN107744591A (zh) | 2017-08-04 | 2017-08-04 | 一种抗癌、治癌的纯食品制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107744591A true CN107744591A (zh) | 2018-03-02 |
Family
ID=61255354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710662824.9A Pending CN107744591A (zh) | 2017-08-04 | 2017-08-04 | 一种抗癌、治癌的纯食品制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107744591A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126092A (zh) * | 1995-07-14 | 1996-07-10 | 李江 | 富硒虫草口服液及其制备方法 |
| CN1304663A (zh) * | 2000-12-12 | 2001-07-25 | 李江 | 富硒北冬虫夏草罐头及其制备方法 |
| CN102210820A (zh) * | 2011-05-24 | 2011-10-12 | 姜爱军 | 一种治疗白血病的中药组合物 |
-
2017
- 2017-08-04 CN CN201710662824.9A patent/CN107744591A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1126092A (zh) * | 1995-07-14 | 1996-07-10 | 李江 | 富硒虫草口服液及其制备方法 |
| CN1304663A (zh) * | 2000-12-12 | 2001-07-25 | 李江 | 富硒北冬虫夏草罐头及其制备方法 |
| CN102210820A (zh) * | 2011-05-24 | 2011-10-12 | 姜爱军 | 一种治疗白血病的中药组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102204612B (zh) | 包括活性紫杉的中药组合物及其制备方法 | |
| KR20200106577A (ko) | 복합 식물 추출물을 포함하는 항산화, 항염증 및 붓기 완화용 조성물 | |
| KR101419463B1 (ko) | 간질환 예방 및 치료용 생약 조성물 | |
| CN105597071A (zh) | 用于治疗仔猪缺铁性贫血的中药组合物及其制备方法 | |
| KR101140322B1 (ko) | 홍삼, 당귀, 천궁, 황기, 대추, 백출, 작약, 감초, 계피 및 숙지황으로 이루어진 한방 혼합 침출차 조성물 및 그 제조방법 | |
| CN104306659B (zh) | 一种治疗2型糖尿病的中药组合物 | |
| CN103892475B (zh) | 保健文胸 | |
| CN104338031A (zh) | 生白方中药饮片组合制剂、制备方法及组合包装 | |
| CN110973625A (zh) | 基于火麻仁的护肝醒酒组合物及其制备方法和应用 | |
| CN103719997B (zh) | 一种番石榴固体饮料 | |
| CN109527577A (zh) | 一种具有解酒护肝功能的组合物 | |
| CN105211441A (zh) | 一种降压降脂的丹参叶保健茶及其制备方法 | |
| CN107970368A (zh) | 一种帮助戒烟的鱼腥草口服液及其制备方法 | |
| CN107744591A (zh) | 一种抗癌、治癌的纯食品制剂 | |
| KR101544000B1 (ko) | 생약 혼합물의 추출물을 함유하는 피부 미백용 조성물 | |
| CN108813500B (zh) | 具有补中益气、养血安神和调节人体机能的养生蜂蜜膏 | |
| CN105560984B (zh) | 一种益气健脾的中药组合物 | |
| KR100885480B1 (ko) | 한방 미백 조성물 및 그 제조방법 | |
| CN106072513B (zh) | 一种具有补血功效的食品、保健品或药物组合物及其制备方法 | |
| CN108936652A (zh) | 一种降糖降压的保健果冻及其制备方法 | |
| CN107519429B (zh) | 具有改善脾胃和促进通便排毒功能的中药组合物及制法 | |
| KR102246636B1 (ko) | 천연 추출물을 포함하는 항염증용 조성물 | |
| CN105663445A (zh) | 一种防治心脑血管疾病的降三高茶核酸生产工艺 | |
| CN106421469A (zh) | 一种治疗白发的中药组合物 | |
| CN113016972A (zh) | 一种含有园艺黄荆的固体饮料 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180302 |